Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:http://oc1dean.blogspot.com/2010/11/my-background-story_8.html

Sunday, July 31, 2016

Resveratrol appears to restore blood-brain barrier integrity in Alzheimer's disease

So how much red wine should stroke patients be drinking to maybe solve this cause of the neuronal cascade of death?  Does this also restore blood brain barrier integrity in stroke? Inquiring minds want to know.
http://www.mdlinx.com/internal-medicine/top-medical-news/article/2016/07/28/12

Georgetown University Medical Center News
Resveratrol, given to Alzheimer’s patients, appears to restore the integrity of the blood–brain barrier, reducing the ability of harmful immune molecules secreted by immune cells to infiltrate from the body into brain tissues, say researchers at Georgetown University Medical Center. The reduction in neuronal inflammation slowed the cognitive decline of patients, compared to a matching group of placebo–treated patients with the disorder. The laboratory data provide a more complete picture of results from a clinical trial studying resveratrol in Alzheimer’s disease that was first reported in 2015. The new findings will be presented at the Alzheimer’s Association International Conference 2016 in Toronto on July 27th. According to the researchers, this study suggests that some of the immune molecules that can cause inflammation in the blood can enter the brain through a leaky blood–brain barrier. “These findings suggest that resveratrol imposes a kind of crowd control at the border of the brain. The agent seems to shut out unwanted immune molecules that can exacerbate brain inflammation and kill neurons,” says neurologist Charbel Moussa, MD, PhD, scientific and clinical research director of the GUMC Translational Neurotherapeutics Program. “These are very exciting findings because it shows that resveratrol engages the brain in a measurable way, and that the immune response to Alzheimer’s disease comes, in part, from outside the brain.” In this new study, Moussa and Turner found that treated patients had a 50 percent reduction in matrix metalloproteinase–9 (MMP–9) levels in the cerebrospinal fluid. MMP–9 is decreased when sirtuin1 (SIRT1) is activated. High levels of MMP–9 cause a breakdown in the blood–brain barrier, allowing proteins and molecules from the body to enter the brain. Normally low MMP–9 levels maintain the barrier, say the researchers.

No comments:

Post a Comment